My­lan share­hold­ers late last week voted to re-elect its board mem­bers at their an­nual meet­ing, de­spite pres­sure to oust se­lect ex­ec­u­tives amid pub­lic and reg­u­la­tory back­lash for the sky­rock­et­ing price of EpiPens.

Modern Healthcare - - LATE NEWS -

Share­hold­ers re­jected pro­posed ex­ec­u­tive pay pack­ages at the meet­ing. For­mer CEO and cur­rent My­lan Chair­man Robert Coury re­ceived a $98 mil­lion com­pen­sa­tion pack­age in 2016, and he and other top ex­ec­u­tives would have re­ceived bonuses un­der the ex­ec­u­tive pay pro­pos­als if the stock price hit cer­tain bench­marks by the end of next year. The drug’s price now tops $600, an increase of more than 500% since 2007, when My­lan bought rights to the drug.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.